Trial Profile
Prospective Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - the EUROPE-trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Myelodysplastic syndromes; Thrombocytopenia
- Focus Biomarker; Therapeutic Use
- Acronyms EUROPE
- 01 Oct 2022 Results assessing the predictive value of biomarkers on the clinical efficacy and safety of single agent romiplostim treatment in patients with lower-risk myelodysplastic neoplasms and thrombocytopenia, published in the Leukemia.
- 17 Jun 2022 Results assessing efficacy and overall safety of ROM in subgroup of LR-MDS patients with thrombocytopenia, presented at the 27th Congress of the European Haematology Association
- 22 Jul 2021 Status changed from active, no longer recruiting to completed.